The estimated Net Worth of Susan Horvath is at least $322 Thousand dollars as of 30 January 2023. Ms Horvath owns over 4,444 units of Panbela Therapeutics stock worth over $6,258 and over the last 4 years she sold PBLA stock worth over $0. In addition, she makes $316,000 as VP of Fin., CFO, and Sec. & Treasurer at Panbela Therapeutics.
Sign up
Ms Horvath PBLA stock SEC Form 4 insiders trading
Ms has made over 1 trades of the Panbela Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 4,444 units of PBLA stock worth $1,555 on 30 January 2023.
The largest trade she's ever made was buying 4,444 units of Panbela Therapeutics stock on 30 January 2023 worth over $1,555. On average, Ms trades about 1,111 units every 0 days since 2021. As of 30 January 2023 she still owns at least 17,880 units of Panbela Therapeutics stock.
You can see the complete history of Ms Horvath stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Susan Horvath biography
Susan Horvath is the VP of Fin., CFO, Sec. & Treasurer at Panbela Therapeutics.
What is the salary of Ms Horvath?
As the VP of Fin., CFO, and Sec. & Treasurer of Panbela Therapeutics, the total compensation of Ms Horvath at Panbela Therapeutics is $316,000. There are 1 executives at Panbela Therapeutics getting paid more, with Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. having the highest compensation of $369,924.
How old is Ms Horvath?
Ms Horvath is 62, she's been the VP of Fin., CFO, and Sec. & Treasurer of Panbela Therapeutics since . There are 1 older and 1 younger executives at Panbela Therapeutics. The oldest executive at Panbela Therapeutics Inc. is Dr. Suzanne Gagnon, 64, who is the Chief Medical Officer & Director.
What's Ms Horvath's mailing address?
Susan's mailing address filed with the SEC is 712 VISTA BLVD #305, , WACONIA, MN, 55387.
Insiders trading at Panbela Therapeutics
Over the last 4 years, insiders at Panbela Therapeutics have traded over $51,741 worth of Panbela Therapeutics stock and bought 406,888 units worth $0 . The most active insiders traders include Sachs Group Incgoldman Sach..., Donald Robert Schemel, and Michael T. Cullen. On average, Panbela Therapeutics executives and independent directors trade stock every 67 days with the average trade being worth of $27,986. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 8 November 2023, trading 72,874 units of PBLA stock currently worth $51,741.
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
What does Panbela Therapeutics's logo look like?
Complete history of Ms Horvath stock trades at Panbela Therapeutics
Panbela Therapeutics executives and stock owners
Panbela Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.,
CEO, Pres & Director -
Susan Horvath,
VP of Fin., CFO, Sec. & Treasurer -
Dr. Elizabeth Bruckheimer Ph.D.,
VP & Chief Scientific Officer -
Dr. Suzanne Gagnon,
Chief Medical Officer & Director -
Tammy Groene,
VP of Operations -
Dr. Thomas X. Neenan Ph.D.,
Co-Founder & Chief Scientific Officer -
Suzanne Gagnon,
Director -
Paul W. Schaffer,
Director -
Jeffrey S Mathiesen,
Director -
Susan Horvath,
V.P. of Finance & CFO -
Michael T. Cullen,
Director -
Jennifer K. Simpson,
President and CEO -
Donald Robert Schemel,
Director -
Arthur Fratamico,
Director -
Sachs Group Incgoldman Sach...,
-
Jeffrey E. Jacob,
Director -
Daniel Donovan,
Director